"id","instanceType","versionIdentifier","rationale","uuid:ID"
"StudyVersion_1","StudyVersion","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","81dff110-6216-4c16-91fb-f9f335e4e49f"
